Altamira Therapeutics Announces Publication of Positive Results From Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal

Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- Detailed results from randomized controlled Bentrio trial in seasonal allergic rhinitis published in Allergy journal Study met primary efficacy

Altamira TherapeuticsApr 24 12:00

Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading small-capitalization equity research and conference provider, will host its Spotlight Investor Conference on April 18, 2024. The

GlobeNewswireApr 17 20:00

Altamira Therapeutics Announces 2024 Annual Meeting

TipRanksApr 17 05:57

Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO)

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has initiated coverage of Altamira Therapeutics Ltd.

GlobeNewswireApr 15 20:00

Altamira Therapeutics FY EPS $(16.47) Sales $284.47K Down From $330.37K YoY

Altamira Therapeutics (NASDAQ:CYTO) reported quarterly losses of $(16.47) per share. This is a 97.38 percent increase over losses of $(629.80) per share from the same period last year. The company re

BenzingaApr 10 21:21

Altamira Therapeutics (CYTO.US): The 2023 FY financial report achieved revenue of US$284.47 million, previous value of US$3303.7 million; earnings per share were -16.47 dollars, previous value of -629.80 dollars.

Altamira Therapeutics (CYTO.US): The 2023 FY financial report achieved revenue of US$284.47 million, previous value of US$3303.7 million; earnings per share were -16.47 dollars, previous value of -629.80 dollars.

Zhitong FinanceApr 10 20:12